{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:27:14Z","timestamp":1785835634924,"version":"3.56.0"},"reference-count":31,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Rabies immune globulin (RIG) is an indispensable component of rabies post-exposure prophylaxis (PEP) because it provides passive immunity to prevent this otherwise inescapably fatal disease in Category III exposed patients. Even with decades of development, RIG products are still criticized for their high cost, lot-to-lot variation, and potential safety issues. They remain largely unattainable in most developing regions of the world, where demand is highest. In recent years, monoclonal antibodies (MAbs) have become widely accepted as safer and more cost-effective alternatives to RIG products. As an example, SYN023 is a 1:1 cocktail of two humanized anti-rabies MAbs previously shown to display extensive neutralizing capabilities. Here, we further assessed the efficacy of SYN023 in animal models of rabies, and found that SYN023 afforded protection equal to a standard dose of human RIG (HRIG) at 0.03 mg\/kg in Syrian hamsters and 0.1 mg\/kg in beagles. Potential interference with vaccine-induced immunity was analyzed for the MAbs at these concentrations. While individual MAbs did not interfere with vaccine response, SYN023 at dosages of 0.1 mg\/kg and above resulted in reduced neutralizing antibody titers similar to HRIG. Thus, the in vivo characterization of SYN023 supports its utility in human rabies PEP as an efficacious alternative to RIG products.<\/jats:p>","DOI":"10.3390\/tropicalmed5010031","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T08:59:47Z","timestamp":1582275587000},"page":"31","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models"],"prefix":"10.3390","volume":"5","author":[{"given":"Tzu-Yuan","family":"Chao","sequence":"first","affiliation":[{"name":"Synermore Biologics Co., Ltd., 6F-6, No. 5, Aly. 22, Ln. 513, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-feng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory of Epidemiology and Key Laboratory of Jilin Provincial Zoonosis Control and Prevention, Military Veterinary Research Institute, Academy of Military Medical Sciences, 666 Liuying West Road, Jingyue Economic Development Zone, Changchun, Jilin 130122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[{"name":"Synermore Biologics Co., Ltd., 6F-6, No. 5, Aly. 22, Ln. 513, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tsao","sequence":"additional","affiliation":[{"name":"Synermore Biologics Co., Ltd., 6F-6, No. 5, Aly. 22, Ln. 513, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Rupprecht","sequence":"additional","affiliation":[{"name":"LYSSA LLC, Cummings, GA 30040, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(02)00287-6","article-title":"Rabies re-examined","volume":"2","author":"Rupprecht","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","unstructured":"(2019, December 09). Rabies. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/rabies."},{"key":"ref_3","unstructured":"World Health Organization (2019, December 09). WHO Expert Consultation on Rabies, Third Report. Available online: https:\/\/apps.who.int\/iris\/bitstream\/10665\/85346\/1\/9789241209823_eng.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1073\/pnas.89.15.7252","article-title":"Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system","volume":"89","author":"Dietzschold","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","unstructured":"(2019, December 09). Why a Simple, Lifesaving Rabies Shot Can Cost $10,000 in America. Available online: https:\/\/www.vox.com\/policy-and-politics\/2018\/2\/7\/16851134\/rabies-treament-expensive-emergency-room."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"A132","DOI":"10.1016\/j.vaccine.2018.11.004","article-title":"Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline","volume":"37","author":"Sparrow","year":"2019","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"M\u00fcller, T., Dietzschold, B., Ertl, H., Fooks, A.R., Freuling, C., Fehlner-Gardiner, C., Kliemt, J., Meslin, F.X., Franka, R., and Rupprecht, C.E. (2009). Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/annotation\/df98339d-6bdb-40ed-af83-cc38b249264a"},{"key":"ref_8","first-page":"67","article-title":"Human monoclonal antibody and vaccine approaches to prevent human rabies","volume":"317","author":"Nagarajan","year":"2008","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants","volume":"79","author":"Bakker","year":"2005","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","article-title":"Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates","volume":"25","author":"Sloan","year":"2007","journal-title":"Vaccine"},{"key":"ref_11","first-page":"1","article-title":"Monoclonal antibodies for the prevention of rabies: Theory and clinical practice","volume":"4","author":"Nagarajan","year":"2014","journal-title":"Antib. Technol. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.47203\/IJCH.2018.v30i03.004","article-title":"Safety of new indigenous human Rabies Monoclonal Antibody (RMAb) for post exposure prophylaxis","volume":"30","author":"Shivalingaiah","year":"2018","journal-title":"Indian J. Community Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: A phase 2\/3, randomized, single-blind, noninferiority, controlled study","volume":"6","author":"Gogtay","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","first-page":"1","article-title":"Recombinant monoclonal antibodies for rabies post-exposure prophylaxis","volume":"83","author":"Ilina","year":"2018","journal-title":"Biochemistry"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chao, T.Y., Ren, S., Shen, E., Moore, S., Zhang, S.F., Chen, L., Rupprecht, C.E., and Tsao, E. (2017). SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0006133"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1080\/22221751.2019.1683436","article-title":"Antigenic variations of recent street rabies virus","volume":"8","author":"Wang","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"ref_17","first-page":"33","article-title":"Characteristics of rabies street virus strain BD06 for challenge test in dogs","volume":"27","author":"Liu","year":"2014","journal-title":"Chin. J. Biol."},{"key":"ref_18","unstructured":"Meslin, F.X., Kaplan, M.M., and Koprowski, H. (1996). The Fluorescent Antibody Test. Laboratory Techniques in Rabies, World Health Organization. [4th ed.]."},{"key":"ref_19","unstructured":"Meslin, F.X., Kaplan, M.M., and Koprowski, H. (1996). A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody. Laboratory Techniques in Rabies, World Health Organization. [4th ed.]."},{"key":"ref_20","first-page":"303","article-title":"Rabies immune globulin of human origin: Preparation and dosage determination in non-exposed volunteer subjects","volume":"45","author":"Cabasso","year":"1971","journal-title":"Bull. World Health Organ."},{"key":"ref_21","unstructured":"WHO (2018). Rabies Vaccines: WHO Position Paper-April 2018. Wkly. Epidemiol. Rec., 93, 201\u2013220. Available online: https:\/\/www.who.int\/rabies\/resources\/who_wer9316\/en\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4014\/jmb.1010.10003","article-title":"Proteomic profiles of mouse neuro N2a cells infected with variant virulence of rabies viruses","volume":"21","author":"Wang","year":"2011","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Franka, R., Carson, W.C., Ellison, J.A., Taylor, S.T., Smith, T.G., Kuzmina, N.A., Kuzmin, I.V., Marissen, W.E., and Rupprecht, C.E. (2017). In vivo efficacy of a cocktail of human monoclonal antibodies (CL184) against diverse North American bat rabies virus variants. Trop. Med. Infect. Dis., 2.","DOI":"10.3390\/tropicalmed2030048"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.15252\/emmm.201505986","article-title":"Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis","volume":"8","author":"Minola","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(83)90288-X","article-title":"An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis","volume":"2","author":"Warrell","year":"1983","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0092-1157(82)80013-9","article-title":"A clinical study of Merieux human rabies immune globulin","volume":"10","author":"Helmick","year":"1982","journal-title":"J. Biol. Stand."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0264-410X(88)90225-3","article-title":"Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment","volume":"6","author":"Vodopija","year":"1988","journal-title":"Vaccine"},{"key":"ref_28","first-page":"491","article-title":"Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: A field trial in Indonesia","volume":"76","author":"Lang","year":"1998","journal-title":"Bull. World Health Organ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0264-410X(94)90308-5","article-title":"A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis","volume":"12","author":"Suntharasamai","year":"1994","journal-title":"Vaccine"},{"key":"ref_30","first-page":"79","article-title":"Safety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate\/chromatography purified","volume":"10","author":"Hanna","year":"2018","journal-title":"Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2460\/javma.237.12.1395","article-title":"Evaluation of a postexposure rabies prophylaxis protocol for domestic animals in Texas: 2000\u20132009","volume":"237","author":"Wilson","year":"2010","journal-title":"J. Am. Vet. Med. Assoc."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/5\/1\/31\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:59:37Z","timestamp":1760173177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/5\/1\/31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["tropicalmed5010031"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed5010031","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]}}}